Document Detail

Growth hormone administration conserves lean body mass during dietary restriction in obese subjects.
MedLine Citation:
PMID:  3558728     Owner:  NLM     Status:  MEDLINE    
Because weight-reducing diets result in loss of lean body tissue as well as fat, we sought to determine whether injections of GH might facilitate the preservation of nitrogen and accelerate the loss of body fat during dietary restriction. The dietary intake of 8 obese subjects was restricted to 24 Cal/kg ideal BW and 1 g protein/kg for 11 weeks. During weeks 3-5, 4 subjects were given a total of 10 im injections of recombinant methionyl human GH, 1 morning injection every 48 h in a dosage of 0.1 mg/kg ideal BW. The other 4 subjects were given injections of vehicle. During weeks 8-10, the subjects who had received GH previously were given vehicle and vice versa. While receiving GH injections the mean daily nitrogen deficit [0.35 +/- 2.14 (+/- SD) g/day] was significantly less than the loss during injection of vehicle (2.21 +/- 1.45 g/day; P less than 0.001). Although three of six subjects lost 190% more fat (as determined by hydrostatic weighing) while receiving GH, the difference in group mean fat loss during GH injection was not significantly greater than that during injection of vehicle (3.06 +/- 1.39 kg lost with GH vs. 2.64 +/- 1.08 kg lost with vehicle; P = NS). In parallel with the changes in nitrogen balance, GH produced a significant increase in the mean plasma somatomedin-C/insulin-like growth factor I concentration. From a mean pretreatment value of 1.06 +/- 0.28 U/mL, a maximal value of 3.20 +/- 1.60 U/mL was achieved after 12 days of GH injection (P less than 0.001). Somatomedin-C/insulin-like growth factor I concentrations did not change during injection of vehicle. During GH injection weight loss was attenuated because of fluid retention. If weight loss was determined 1 week after the end of GH administration, however, the total weight loss (3.42 +/- 1.73 kg) was not significantly different from that during the 3 weeks of vehicle administration and the following week (4.16 +/- 1.30 kg). Fasting blood glucose and serum insulin concentrations did not change during GH administration, and no glycosuria was detected in morning urine samples. Short term GH administration is effective in decreasing the loss of lean body mass in individuals ingesting restricted diets. However, fat loss was not accelerated.
D R Clemmons; D K Snyder; R Williams; L E Underwood
Related Documents :
20938438 - Effects of lupin-enriched foods on body composition and cardiovascular disease risk fac...
3558728 - Growth hormone administration conserves lean body mass during dietary restriction in ob...
12566138 - Low-fat diets are preferred.
21727918 - Dietary factors associated with hypertension.
10086228 - Behavioral specificity of effects of 2-mercaptoacetate on independent ingestion in deve...
21673458 - Comparison of preventive effect on cardiovascular events with different statins. -the c...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  64     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1987 May 
Date Detail:
Created Date:  1987-05-20     Completed Date:  1987-05-20     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  878-83     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adipose Tissue / metabolism
Body Composition* / drug effects
Body Weight / drug effects
Combined Modality Therapy
Diet, Reducing*
Growth Hormone / adverse effects,  pharmacology,  therapeutic use*
Insulin-Like Growth Factor I / blood
Middle Aged
Nitrogen / metabolism
Obesity / diet therapy*,  drug therapy
Grant Support
Reg. No./Substance:
67763-96-6/Insulin-Like Growth Factor I; 7727-37-9/Nitrogen; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rising plasma levels of 19-nortestosterone throughout pregnancy: determination by radioimmunoassay a...
Next Document:  Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin-C levels.